Gameto Raises $33 Million in Series B Financing to Advance Development and Commercialization of Novel Fertility TreatmentsOversubscribed round led by Two Sigma Ventures and RA Capital

Gameto在B系列融资中筹集3300万美元，以推动新型生育治疗的开发和商业化

Company has raised $73 million to dateNEW YORK, May 29, 2024-- Gameto, a biotechnology company dedicated to advancing treatment options in women's health, has closed an oversubscribed $33 million Series B financing round, led by Two Sigma Ventures with RA Capital and participation from existing investors, including Insight Partners, Future Ventures, and BOLD Capital Partners.

截至2024年5月29日，该公司迄今已筹集7300万美元资金。致力于推进女性健康治疗方案的生物技术公司Gameto完成了一轮3300万美元超额认购的B系列融资，由两个Sigma Ventures牵头，RA Capital和现有投资者（包括Insight Partners、Future Ventures和BOLD Capital Partners）参与。

Gameto's investor group is also joined by Olivia Walton's Ingeborg Investments, Stacey Bendet Eisner, Founder, CEO, and Creative Director of alice + olivia, and Chelsea Hirschhorn, Founder and CEO of Frida..

奥利维亚·沃尔顿（Olivia Walton）的英格堡投资公司（Ingeborg Investments）、爱丽丝·奥利维亚（alice+Olivia）创始人、首席执行官兼创意总监斯泰西·本德·艾斯纳（Stacey Bendet Eisner）以及弗里达（Frida）创始人兼首席执行官切尔西·赫施霍恩（Chelsea Hirschhorn）也加入了加梅托。。

This latest funding brings Gameto's total capital raised to $73 million. In the U.S., the financing will support the clinical development of Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body. Following productive discussions with the U.S.

这项最新资金使Gameto的总资金达到7300万美元。在美国，这笔资金将支持Fertilo的临床开发，Fertilo是他们的新型研究性体外成熟（IVM）解决方案，其中包含工程化卵巢支持细胞（OSC），可在体外成熟卵子。在与美国进行富有成效的讨论之后。

Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials, subject to the completion of certain assay and manufacturing requirements. The funding will continue to support the commercial launches of Fertilo in Australia and Latin America where it is already being used in the clinic..

食品和药物管理局，Gameto获得了初步批准，可以进行第三阶段试验，但必须完成某些测定和制造要求。这笔资金将继续支持Fertilo在澳大利亚和拉丁美洲的商业推出，该产品已在诊所中使用。。

'I am proud of the strong scientific foundation, driven and high performing team, innovative pipeline and encouraging data that we have cultivated at Gameto, and I am incredibly excited to amplify and build upon this momentum with the addition of leading investors with extensive expertise in reproductive medicine,' said Dr.

“我为我们在Gameto培养的强大的科学基础、驱动力和高绩效的团队、创新的渠道和令人鼓舞的数据感到骄傲，我非常兴奋能够通过增加在生殖医学领域具有广泛专业知识的领先投资者来扩大和发展这一势头，”Dr。

Dina Radenkovic, Chief Executive Officer and co-founder of Gameto. 'These funds will support our late stage clinical development in the U.S., post-market surveillance outside the U.S. and the creation of a commercial operations function. We are honored to have added the teams at Two Sigma, RA Capital, and others to our stellar investor base, and we're pleased to see increased investor confidence in our platform technology and a recognition of the pressing need for modern treatments in the historically underfunded women's health space, despite a challenging market.

Gameto首席执行官兼联合创始人迪娜·拉登科维奇（DinaRadenkovic）这些资金将支持我们在美国的后期临床开发、美国境外的上市后监测以及商业运营职能的创建。我们很荣幸能够将两西格玛、RA Capital和其他团队加入到我们的明星投资者基础中，我们很高兴看到投资者对我们的平台技术的信心增强，并且认识到在历史上资金不足的女性健康领域迫切需要现代治疗，尽管市场充满挑战。

I believe that each small step we take in investing in women's health can lead to a giant leap in medical breakthroughs and innovation.'.

我相信，我们在投资女性健康方面迈出的每一小步都可以带来医学突破和创新的巨大飞跃。”。

Gameto's novel approach uses cellular engineering to create a pure population of highly potent OSCs from a female clinical-grade human induced pluripotent stem cell (hiPSC) line that recreates the dynamic, bidirectional follicular environment in a dish when co-cultured with immature eggs. This technology is designed to replace hormonal injections and shorten the in vitro fertilization (IVF) and egg freezing cycle from 10-14 days to 2-3 days..

Gameto的新方法使用细胞工程从女性临床级人类诱导多能干细胞（hiPSC）系中创建一个纯的高效OSC群体，当与未成熟卵共培养时，该细胞系在培养皿中重建动态的双向卵泡环境。该技术旨在替代激素注射，将体外受精（IVF）和卵子冷冻周期从10-14天缩短到2-3天。。

'Gameto's pioneering approach to IVF has the potential to impact families and societies on a global scale,' said Dusan Perovic, Partner at Two Sigma Ventures. 'In addition to making treatments much easier and more accessible for women, Gameto's advanced IVF/egg-freezing solution addresses a massive societal need as we're living longer and looking to start families later in life while facing rising female and male infertility rates.

“加梅托开创性的体外受精方法有可能在全球范围内影响家庭和社会，”两西格玛风险投资公司（Two Sigma Ventures）合伙人杜桑·佩罗维奇（DusanPerovic）说除了让女性更容易接受治疗外，Gameto的先进IVF/卵子冷冻解决方案还解决了巨大的社会需求，因为我们的寿命更长，并且希望在以后的生活中建立家庭，同时面临不断上升的女性和男性不育率。

There's also a growing demand for IVF from a broader group of people, such as those with certain genetic disorders now discoverable by carrier screening, and single and same-sex parents starting families, to name a few. By harnessing cutting-edge breakthroughs in genetic sequencing and cellular engineering – tools that didn't exist until recently – Gameto is poised to upend traditional IVF treatments to make them more accessible, convenient, and faster for anyone to start a family.'.

越来越多的人对体外受精的需求也在增长，例如那些患有某些遗传疾病的人，现在可以通过携带者筛查发现，以及单身和同性父母组建家庭等等。通过利用基因测序和细胞工程（直到最近才出现的工具）方面的尖端突破，Gameto准备颠覆传统的IVF治疗方法，使其更容易，更方便，更快地为任何人建立家庭。”。

'It's astounding how little innovation has gone into improving IVF over the past 45 years,' said Laura Stoppel, a Principal at RA Capital Management. 'Gameto is a pioneer in the women's health industry, and we believe Fertilo represents a much-needed option for women as they navigate their fertility journey.'.

RA资本管理公司（RA Capital Management）负责人劳拉·斯托佩尔（LauraStoppel）说，令人惊讶的是，过去45年来，在改善体外受精方面几乎没有创新Gameto是女性健康行业的先驱，我们相信Fertilo是女性在生育过程中急需的选择。”。

'This investment is among the most personal any investor can make,' added Peter Kolchinsky, Managing Partner of RA Capital Management and father of two children. 'Many at our firm have been blessed by what IVF makes possible, and know the ordeal that women tolerate at the outset of that journey just to conceive.

RA资本管理公司（RA Capital Management）管理合伙人、两个孩子的父亲彼得·科尔钦斯基（PeterKolchinsky）补充说，这项投资是所有投资者能做的最私人的投资之一我们公司的许多人都受到了体外受精的祝福，并且知道女性在怀孕之初所忍受的苦难。

To contemplate the importance of easing that burden, of expanding the freedom of many to have children when they are ready, it's hard to overestimate the potential impact of such an advance on humanity, for all of our society, for the rest of time.'.

考虑到减轻这种负担的重要性，扩大许多人准备好要孩子的自由，很难高估这种进步对人类、对我们整个社会、对未来的潜在影响。”。

Gameto is also supported by existing investors including Anne Wojcicki of 23andMe, Bob Nelsen of ARCH Venture Partners, Arcadia Investment Partners, Overwater Ventures, Plum Alley, Lux Capital, FJ Labs, SALT Fund, Myelin VC, TA Ventures, Jack Abraham of Atomic, YES VC and Dan Rose.

Gameto也得到了现有投资者的支持，包括23andMe的安妮·沃西基（AnneWojcicki）、ARCH Venture Partners的鲍勃·尼尔森（BobNelsen）、Arcadia Investment Partners、Overwater Ventures、Plum Alley、Lux Capital、FJ Labs、SALT Fund、Myelin VC、TA Ventures、Atomic的杰克·亚伯拉罕（JackAbraham）、YES VC和丹·。

About Fertilo

关于费蒂洛

Fertilo, Gameto's lead investigational program, is a solution derived from induced pluripotent stem cells (iPSC) and designed to mature eggs outside of the body as part of minimal hormonal stimulation cycles for in vitro fertilization and egg freezing. Gameto's goal in developing Fertilo is to make fertility treatments more convenient, safer, and accessible for a wider patient population.

Gameto的主要研究项目Fertilo是一种源自诱导多能干细胞（iPSC）的解决方案，旨在使卵子在体外成熟，作为体外受精和卵子冷冻的最小激素刺激周期的一部分。Gameto开发Fertilo的目标是使生育治疗更方便，更安全，更广泛的患者群体更容易获得。

Fertilo has received different regulatory classifications in foreign jurisdictions, and after consultation with national regulators, has been cleared for commercialization in Australia and in large markets in Latin America..

Fertilo在外国司法管辖区接受了不同的监管分类，在与国家监管机构协商后，已获准在澳大利亚和拉丁美洲的大型市场进行商业化。。

About Gameto

关于Gameto

Gameto is a biotechnology company developing novel treatment solutions for women's health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body.

Gameto是一家为女性健康开发新型治疗方案的生物技术公司，从不孕症开始。Gameto汇集了一支经验丰富、富有远见和激情的科学管理团队，开发一套产品套件，为女性的整个生育过程提供支持。Gameto的主导项目Fertilo旨在通过减少体外成熟卵子的激素注射，使体外受精和卵子冷冻更短，更安全，更容易获得。

Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and founder of one of North America's largest fertility networks Prelude Fertility, Martin Varsavsky, as Chairman. For more information, go to gametogen.com or follow us on Twitter and Instagram @gametogen and on LinkedIn.Contact: .

Gameto由医生出身的企业家Dina Radenkovic领导，Dina Radenkovic担任首席执行官和连续企业家，也是北美最大的生育网络之一Prelude fertility的创始人，Martin Varsavsky担任主席。有关更多信息，请访问gametogen.com或在Twitter、Instagram@gametogen和LinkedIn上关注我们。联系人：。。

Investor Contact

投资者联系人

Kylie Jordan

凯莉·乔丹。

kylie@gametogen.com

kylie@gametogen.com

Press Contact

新闻联系人

Alexis Feinberg

亚历克西斯·范伯格

GametoPR@westwicke.com

GametoPR@westwicke.com